| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Quest for Health Equity (Q4HE) and several Quest employees participated in an Earth Day weekend community event with the Black Church Food Security Network; an association of congregations, farmers, food advocates, and community activists working together to create an alternative food system in the Baltimore metropolitan area.
Before the COVID-19 pandemic, at Quest Diagnostics, we were in the midst of challenging what a traditional lab looked like to enhance quality, capacity, and efficiency while improving the employee experience. We remained committed to moving our East Region lab operations from our legacy lab in Teterboro, NJ, to Clifton, NJ, despite the pandemic challenges. The Clifton lab was built for our employees, with our employees.
As drugs to treat Alzheimer's disease come to market, led by the US Food and Drug Administration approval of Biogen's Aduhelm nearly a year ago, diagnostic tests to detect the disease are following suit. Blood-based biomarker tests have gained particular prominence, as they're less invasive and cheaper than both PET imaging and cerebrospinal fluid (CSF) biomarker testing – two current standards of care for patients presenting with Alzheimer's symptoms. Michael Racke, medical director for neurology at Quest Diagnostics, said in an interview that plasma tests are beneficial because they can be used to screen patients who are "normal cognitively" and may be candidates for intervention before they decline.
"Allergy and Omicron symptoms may mimic one another," Jeffrey Dlott, MD, senior medical director at Quest Diagnostics, told Health. "Because of this, someone may confuse COVID symptoms for allergy symptoms and not take the proper precautions to reduce spread." Here's what to know about how similar Omicron symptoms can look compared to allergies, and steps to take to confirm either diagnosis.
Liquid biopsy is proving itself as both an efficacious and cost-effective way to provide a cancer diagnosis to patients. However, to fully realize its potential there will need to be a paradigm shift with a focus on primary care physicians and collaboration across the healthcare enterprise. By Yuri Fesko, MD